PMC:7600245 / 30118-30451 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T123","span":{"begin":184,"end":191},"obj":"Body_part"},{"id":"T124","span":{"begin":246,"end":249},"obj":"Body_part"},{"id":"T125","span":{"begin":323,"end":326},"obj":"Body_part"}],"attributes":[{"id":"A123","pred":"fma_id","subj":"T123","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A124","pred":"fma_id","subj":"T124","obj":"http://purl.org/sig/ont/fma/fma278683"},{"id":"A125","pred":"fma_id","subj":"T125","obj":"http://purl.org/sig/ont/fma/fma278683"}],"text":"l benefit for lopinavir/ritonavir when used with ribavirin and/or INFs against MERS-CoV and SARS-CoV [88,93,94]. Yet, coronavirus proteases, including Mpro, do not have a C2-symmetric protein architecture which is the target of lopinavir and all HIV-1 protease inhibitors. This subsequently sheds doubts on the prospect of HIV-1 aspa"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T112","span":{"begin":92,"end":100},"obj":"Disease"}],"attributes":[{"id":"A112","pred":"mondo_id","subj":"T112","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"l benefit for lopinavir/ritonavir when used with ribavirin and/or INFs against MERS-CoV and SARS-CoV [88,93,94]. Yet, coronavirus proteases, including Mpro, do not have a C2-symmetric protein architecture which is the target of lopinavir and all HIV-1 protease inhibitors. This subsequently sheds doubts on the prospect of HIV-1 aspa"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T278","span":{"begin":169,"end":173},"obj":"http://purl.obolibrary.org/obo/CLO_0001649"}],"text":"l benefit for lopinavir/ritonavir when used with ribavirin and/or INFs against MERS-CoV and SARS-CoV [88,93,94]. Yet, coronavirus proteases, including Mpro, do not have a C2-symmetric protein architecture which is the target of lopinavir and all HIV-1 protease inhibitors. This subsequently sheds doubts on the prospect of HIV-1 aspa"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T423","span":{"begin":14,"end":33},"obj":"Chemical"},{"id":"T424","span":{"begin":14,"end":23},"obj":"Chemical"},{"id":"T425","span":{"begin":24,"end":33},"obj":"Chemical"},{"id":"T426","span":{"begin":49,"end":58},"obj":"Chemical"},{"id":"T427","span":{"begin":171,"end":173},"obj":"Chemical"},{"id":"T428","span":{"begin":184,"end":191},"obj":"Chemical"},{"id":"T429","span":{"begin":228,"end":237},"obj":"Chemical"},{"id":"T430","span":{"begin":252,"end":271},"obj":"Chemical"},{"id":"T432","span":{"begin":261,"end":271},"obj":"Chemical"}],"attributes":[{"id":"A423","pred":"chebi_id","subj":"T423","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A424","pred":"chebi_id","subj":"T424","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A425","pred":"chebi_id","subj":"T425","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A426","pred":"chebi_id","subj":"T426","obj":"http://purl.obolibrary.org/obo/CHEBI_63580"},{"id":"A427","pred":"chebi_id","subj":"T427","obj":"http://purl.obolibrary.org/obo/CHEBI_30083"},{"id":"A428","pred":"chebi_id","subj":"T428","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A429","pred":"chebi_id","subj":"T429","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A430","pred":"chebi_id","subj":"T430","obj":"http://purl.obolibrary.org/obo/CHEBI_37670"},{"id":"A431","pred":"chebi_id","subj":"T430","obj":"http://purl.obolibrary.org/obo/CHEBI_60258"},{"id":"A432","pred":"chebi_id","subj":"T432","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"l benefit for lopinavir/ritonavir when used with ribavirin and/or INFs against MERS-CoV and SARS-CoV [88,93,94]. Yet, coronavirus proteases, including Mpro, do not have a C2-symmetric protein architecture which is the target of lopinavir and all HIV-1 protease inhibitors. This subsequently sheds doubts on the prospect of HIV-1 aspa"}

{"project":"LitCovid-sentences","denotations":[{"id":"T223","span":{"begin":113,"end":272},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"l benefit for lopinavir/ritonavir when used with ribavirin and/or INFs against MERS-CoV and SARS-CoV [88,93,94]. Yet, coronavirus proteases, including Mpro, do not have a C2-symmetric protein architecture which is the target of lopinavir and all HIV-1 protease inhibitors. This subsequently sheds doubts on the prospect of HIV-1 aspa"}

{"project":"LitCovid-PubTator","denotations":[{"id":"847","span":{"begin":151,"end":155},"obj":"Gene"},{"id":"852","span":{"begin":79,"end":87},"obj":"Species"},{"id":"853","span":{"begin":92,"end":100},"obj":"Species"},{"id":"854","span":{"begin":118,"end":129},"obj":"Species"},{"id":"855","span":{"begin":246,"end":251},"obj":"Species"},{"id":"856","span":{"begin":323,"end":328},"obj":"Species"},{"id":"861","span":{"begin":14,"end":33},"obj":"Chemical"},{"id":"862","span":{"begin":49,"end":58},"obj":"Chemical"},{"id":"863","span":{"begin":228,"end":237},"obj":"Chemical"}],"attributes":[{"id":"A847","pred":"tao:has_database_id","subj":"847","obj":"Gene:8673700"},{"id":"A852","pred":"tao:has_database_id","subj":"852","obj":"Tax:1335626"},{"id":"A853","pred":"tao:has_database_id","subj":"853","obj":"Tax:694009"},{"id":"A854","pred":"tao:has_database_id","subj":"854","obj":"Tax:11118"},{"id":"A855","pred":"tao:has_database_id","subj":"855","obj":"Tax:11676"},{"id":"A856","pred":"tao:has_database_id","subj":"856","obj":"Tax:11676"},{"id":"A861","pred":"tao:has_database_id","subj":"861","obj":"MESH:C558899"},{"id":"A862","pred":"tao:has_database_id","subj":"862","obj":"MESH:D012254"},{"id":"A863","pred":"tao:has_database_id","subj":"863","obj":"MESH:D061466"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"l benefit for lopinavir/ritonavir when used with ribavirin and/or INFs against MERS-CoV and SARS-CoV [88,93,94]. Yet, coronavirus proteases, including Mpro, do not have a C2-symmetric protein architecture which is the target of lopinavir and all HIV-1 protease inhibitors. This subsequently sheds doubts on the prospect of HIV-1 aspa"}